Safety and efficacy in the initiation of IDegLira for the outpatient with type 2 diabetes

Safety and efficacy in the initiation of IDegLira for the outpatient with type 2 diabetes - IDegLira study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000038100

Enrollment

Registered

2019-10-01

Start date

2019-10-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus

Interventions

Administration of IDegLira with Free Style Libre Pro to type 2 diabetes patients. Doses will be adjusted in increments of 1 dose, aiming for a pre-breakfast selfmonitored blood glucose (SMBG) targe

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetes patients who are uncontrolled one or over OHA treatment and are not treated insulin and GLP-1RA.

Exclusion criteria

Exclusion criteria: Sever impaired renal function. (eGFR<30ml/min/1.73m2, end stage in CKD and dialysis) Insulin depended stage (Fasting CPR <0.6 ng/ml) Patients who are decided as inappropriate for other medical reasons

Design outcomes

Primary

Measure	Time frame
Change from baseline in HbA1c, Glycoalbumin and exposure time of hypoglycemia after 8 weeks	—

Secondary

Measure	Time frame
Hypoglycemia Exposure time of hypoglycemia by FGM during first 2 weeks and from 6 week to 8 week after initiation Change in body weight Insulin doses	—

Countries

Japan

Contacts

Public ContactMizuho Yamabe

Murakami Memorial Hospital Department of Internal Medicine

mk-hp2@able.ocn.ne.jp0848-22-3131

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026